M&A / Deals Novartis to acquire Myricx Bio in up to $1.5bn deal Pharmaceutical Business ReviewThe deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments.OncologyRead full story pharminent July 6, 2026 (Last updated: July 6, 2026) Pharmaceutical Business Review The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. Oncology Read full story Post navigation Previous: Roche looks to Astex in $515m breast cancer dealNext: Novartis Acquires UK ADC Specialist Myricx Bio for Up to $1.5 Billion Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026